Abstract: A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.

Abstract: The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Abstract: A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.

Abstract: The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Abstract: The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Abstract: The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane-1-sulfonamide) for regulating kinase activity.

Abstract: The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4?-methoxy-6?-((S)-2-methylpiperazin-1-yl)-3,3?-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Abstract: The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Abstract: The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Abstract: A directional coupler and a receiving or transmitting device. The directional coupler includes: a primary signal line composed of a metal rod; and a coupled signal line composed of a microstrip line in a curved shape on a printed circuit board; wherein the medium between the metal rod and the microstrip line is air. Compared with existing directional coupler, the directional coupler of the embodiments of the disclosure has a lower transmitting loss, a large power capacity, and a high directional qualification. The directional coupler is capable of ensuring a higher passive intermodulation qualification. The advantages of the embodiments of the present disclosure are easier assembly, good uniformity of the qualifications, and adaptability for various application environments. The directional coupler of the disclosure ensures different parameter qualifications, and is simple to assemble, so that the low cost is achieved.

Abstract: A directional coupler and a receiving or transmitting device. The directional coupler includes: a primary signal line composed of a metal rod; and a coupled signal line composed of a micro strip in a curved shape on a printed circuit board; wherein the medium between the metal rod and the micro strip is air. Compared with existing directional coupler, the directional coupler of the embodiments of the disclosure has a lower transmitting loss, a large power capacity, and a high directional qualification. The directional coupler is capable of ensuring a higher passive intermodulation qualification. The advantages of the embodiments of the present disclosure are easier assembly, good uniformity of the qualifications, and adaptability for various application environments. The directional coupler of the disclosure ensures different parameter qualifications, and is simple to assemble, so that the low cost is achieved.